SEC Form 4 · accession 0000899243-19-000179
Spero Therapeutics, Inc. · SPRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cristina Larkin
Officer — Chief Operating Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 2, 2019 · 7:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001701108
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.26 | Jan 2, 2019 | A | 65,000 | A | — | Jan 2, 2029 | Common Stock | 65,000 | 65,000 | D |
Explanation of responses
- F1The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.